Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A. McArthur, Axel Hauschild, John B.A.G. Haanen et al.|The Lancet Oncology|2014Cited by 978
Conditional Reprogramming Modeling of Bladder Cancer for Clinical TranslationDanyal Daneshdoust, Xuefeng Liu, Ming Yin et al.|Cells|2023Cited by 6